EP1622684A4 - Compositions and methods relating to novel compounds and targets thereof - Google Patents

Compositions and methods relating to novel compounds and targets thereof

Info

Publication number
EP1622684A4
EP1622684A4 EP04775923A EP04775923A EP1622684A4 EP 1622684 A4 EP1622684 A4 EP 1622684A4 EP 04775923 A EP04775923 A EP 04775923A EP 04775923 A EP04775923 A EP 04775923A EP 1622684 A4 EP1622684 A4 EP 1622684A4
Authority
EP
European Patent Office
Prior art keywords
targets
compositions
novel compounds
methods relating
relating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04775923A
Other languages
German (de)
French (fr)
Other versions
EP1622684A2 (en
Inventor
Gary D Glick
Anthony W Opipari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan
Original Assignee
University of Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/427,211 external-priority patent/US7572788B2/en
Priority claimed from US10/634,114 external-priority patent/US20040176358A1/en
Priority claimed from US10/795,535 external-priority patent/US7276348B2/en
Application filed by University of Michigan filed Critical University of Michigan
Publication of EP1622684A2 publication Critical patent/EP1622684A2/en
Publication of EP1622684A4 publication Critical patent/EP1622684A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G01N33/5079Mitochondria
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00Detection of programmed cell death, i.e. apoptosis
EP04775923A 2003-05-01 2004-04-30 Compositions and methods relating to novel compounds and targets thereof Withdrawn EP1622684A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/427,211 US7572788B2 (en) 1999-04-30 2003-05-01 Compositions and methods relating to novel compounds and targets thereof
US10/427,212 US7144880B2 (en) 1999-04-30 2003-05-01 Compositions relating to novel compounds and targets thereof
US10/634,114 US20040176358A1 (en) 1999-04-30 2003-08-04 Compositions and methods relating to novel compounds and targets thereof
US10/795,535 US7276348B2 (en) 1999-04-30 2004-03-08 Compositions and methods relating to F1F0-ATPase inhibitors and targets thereof
PCT/US2004/013455 WO2005004988A2 (en) 2003-05-01 2004-04-30 Compositions and methods relating to novel compounds and targets thereof

Publications (2)

Publication Number Publication Date
EP1622684A2 EP1622684A2 (en) 2006-02-08
EP1622684A4 true EP1622684A4 (en) 2007-07-25

Family

ID=34069318

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04775923A Withdrawn EP1622684A4 (en) 2003-05-01 2004-04-30 Compositions and methods relating to novel compounds and targets thereof

Country Status (6)

Country Link
EP (1) EP1622684A4 (en)
JP (1) JP2007500212A (en)
AU (1) AU2004255153B2 (en)
CA (1) CA2524394C (en)
MX (1) MXPA05011741A (en)
WO (1) WO2005004988A2 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7994313B2 (en) 2005-06-01 2011-08-09 The Regents Of The University Of Michigan Unsolvated benzodiazepine compositions and methods
US8088759B2 (en) 2005-11-01 2012-01-03 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones with therapeutic properties
US8097612B2 (en) 2006-06-09 2012-01-17 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US8188072B2 (en) 2007-11-06 2012-05-29 The Regents Of The University Of Michigan Benzodiazepinone compounds useful in the treatment of skin conditions
US8242109B2 (en) 2007-03-09 2012-08-14 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US8324258B2 (en) 2007-09-14 2012-12-04 The Regents Of The University Of Michigan F1F0-ATPase inhibitors and related methods
US8497307B2 (en) 2008-09-11 2013-07-30 The Regents Of The University Of Michigan Aryl guanidine F1F0-ATPase inhibitors and related methods
US8604023B2 (en) 2009-04-17 2013-12-10 The Regents Of The University Of Michigan 1,4-benzodiazepinone compounds and their use in treating cancer
US8673897B2 (en) 2009-09-18 2014-03-18 The Regents Of The University Of Michigan Benzodiazepinone compounds and methods of treatment using same
US8809323B2 (en) 1999-04-30 2014-08-19 The Regents Of The University Of Michigan Therapeutic applications of pro-apoptotic benzodiazepines
US8815845B2 (en) 2009-11-17 2014-08-26 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
US9126978B2 (en) 2009-11-17 2015-09-08 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7276348B2 (en) 1999-04-30 2007-10-02 Regents Of The University Of Michigan Compositions and methods relating to F1F0-ATPase inhibitors and targets thereof
US20050113460A1 (en) * 1999-04-30 2005-05-26 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US20060025388A1 (en) 1999-04-30 2006-02-02 Glick Gary D Compositions and methods relating to novel compounds and targets thereof
US7572788B2 (en) 1999-04-30 2009-08-11 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
JP2008516973A (en) 2004-10-15 2008-05-22 タケダ サン ディエゴ インコーポレイテッド Kinase inhibitor
JP2008528448A (en) 2005-01-03 2008-07-31 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Compositions and methods relating to novel compounds and targets thereof
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
US7759338B2 (en) 2006-04-27 2010-07-20 The Regents Of The University Of Michigan Soluble 1,4 benzodiazepine compounds and stable salts thereof
US20100120717A1 (en) 2006-10-09 2010-05-13 Brown Jason W Kinase inhibitors
US8598150B1 (en) 2008-04-02 2013-12-03 Jonathan R. Brestoff Composition and method for affecting obesity and related conditions
US8987245B2 (en) 2008-04-02 2015-03-24 Jonathan R. Brestoff Parker Composition and method for affecting obesity and related conditions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010016583A1 (en) * 1995-05-18 2001-08-23 Gary D. Glick Therapeutic application of pro-apoptotic benzodiazepines
WO2003015703A2 (en) * 2001-08-15 2003-02-27 The Regents Of The University Of Michigan Compositions and methods relating to novel benzodiazepine compounds and targets thereof
US20030119029A1 (en) * 1999-04-30 2003-06-26 Regents Of The University Of Michigan Compositions and methods relating to novel benzodiazepine compounds and targets thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6524832B1 (en) * 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010016583A1 (en) * 1995-05-18 2001-08-23 Gary D. Glick Therapeutic application of pro-apoptotic benzodiazepines
US20030119029A1 (en) * 1999-04-30 2003-06-26 Regents Of The University Of Michigan Compositions and methods relating to novel benzodiazepine compounds and targets thereof
EP1398033A2 (en) * 1999-04-30 2004-03-17 The Regents Of The University Of Michigan Use of benzodiazepines for treating autoimmune diseases, inflammations, neoplasies, viral infections and atherosclerosis
WO2003015703A2 (en) * 2001-08-15 2003-02-27 The Regents Of The University Of Michigan Compositions and methods relating to novel benzodiazepine compounds and targets thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BASTIAN E.D. ET AL: "Casein interference in bovine plasmin assays using a synthetic substrate", JOURNAL OF DAIRY SCIENCE, vol. 74, no. 12, December 1991 (1991-12-01), UNITED STATES, pages 4119 - 4124, XP007906550 *
BLATT N B ET AL: "Benzodiazepine-induced superoxide signals B cell apoptosis: mechanistic insigfht and potential therapeutic utility", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 10, no. 8, October 2002 (2002-10-01), pages 1123 - 1132, XP002422965 *
JOHNSON K.M. ET AL.: "Mechanistic basis for therapeutic targeting of the mitochondrial F1F0-ATPase", ACS CHEMICAL BIOLOGY, vol. 1, no. 5, June 2006 (2006-06-01), UNITED STATES, pages 304 - 308, XP007906563 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8809323B2 (en) 1999-04-30 2014-08-19 The Regents Of The University Of Michigan Therapeutic applications of pro-apoptotic benzodiazepines
US7994313B2 (en) 2005-06-01 2011-08-09 The Regents Of The University Of Michigan Unsolvated benzodiazepine compositions and methods
US8791104B2 (en) 2005-11-01 2014-07-29 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones with therapeutic properties
US8088759B2 (en) 2005-11-01 2012-01-03 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones with therapeutic properties
US8097612B2 (en) 2006-06-09 2012-01-17 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US8242109B2 (en) 2007-03-09 2012-08-14 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US8324258B2 (en) 2007-09-14 2012-12-04 The Regents Of The University Of Michigan F1F0-ATPase inhibitors and related methods
US8461153B2 (en) 2007-11-06 2013-06-11 The Regents Of The University Of Michigan Benzodiazepinone compounds useful in the treatment of skin conditions
US8759340B2 (en) 2007-11-06 2014-06-24 The Regents Of The University Of Michigan Benzodiazepinone compounds useful in the treatment of skin conditions
US8188072B2 (en) 2007-11-06 2012-05-29 The Regents Of The University Of Michigan Benzodiazepinone compounds useful in the treatment of skin conditions
US8497307B2 (en) 2008-09-11 2013-07-30 The Regents Of The University Of Michigan Aryl guanidine F1F0-ATPase inhibitors and related methods
US8604023B2 (en) 2009-04-17 2013-12-10 The Regents Of The University Of Michigan 1,4-benzodiazepinone compounds and their use in treating cancer
US8673897B2 (en) 2009-09-18 2014-03-18 The Regents Of The University Of Michigan Benzodiazepinone compounds and methods of treatment using same
US8815845B2 (en) 2009-11-17 2014-08-26 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
US9126978B2 (en) 2009-11-17 2015-09-08 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties

Also Published As

Publication number Publication date
CA2524394C (en) 2011-07-12
WO2005004988A2 (en) 2005-01-20
MXPA05011741A (en) 2006-05-12
AU2004255153A1 (en) 2005-01-20
AU2004255153B2 (en) 2007-11-22
WO2005004988A3 (en) 2006-02-23
EP1622684A2 (en) 2006-02-08
CA2524394A1 (en) 2005-01-20
JP2007500212A (en) 2007-01-11

Similar Documents

Publication Publication Date Title
IL218524A0 (en) Compositions and methods relating to novel compounds and targets thereof
EP1622684A4 (en) Compositions and methods relating to novel compounds and targets thereof
EP1778204A4 (en) Compositions and methods relating to novel compounds and traget thereof
EP1651053A4 (en) Compositions and methods relating to freezer-to-oven doughs
IL172481A (en) Fertilizer compositions
GB0304088D0 (en) Improvements in or relating to organic compositions
GB0220893D0 (en) Improvements in or relating to organic compositions
GB0304083D0 (en) Improvements in or relating to organic compositions
EP1423122A4 (en) Compositions and methods relating to novel benzodiazepine compounds and targets thereof
ZA200508655B (en) Compositions and methods relating to stop-1
GB0303831D0 (en) Improvements in or relating to organic compositions
GB0329907D0 (en) Compositions
GB0327091D0 (en) Improvements in or relating to compositions
GB0327088D0 (en) Improvements in or relating to organic compositions
EP1613352A4 (en) Micro-cluster compositions
GB0305790D0 (en) Novel Composition
GB0318824D0 (en) Novel composition
GB0329597D0 (en) Compositions
GB0302929D0 (en) Nutrient composition
GB0326022D0 (en) Improvements in or relating to organic compositions
GB0326505D0 (en) Improvements in or relating to organic compositions
GB0300602D0 (en) Compositions
GB0324574D0 (en) Novel compositions
GB0328023D0 (en) Novel compositions
ZA200600041B (en) Fertilizer compositions

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051128

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL HR LT LV MK

PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 13/00 20060101ALI20060324BHEP

Ipc: A61K 31/00 20060101ALI20060324BHEP

Ipc: A61K 31/55 20060101AFI20060324BHEP

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/5513 20060101AFI20070323BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20070626

17Q First examination report despatched

Effective date: 20071109

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/50 20060101ALI20160622BHEP

Ipc: A61K 31/5513 20060101AFI20160622BHEP

Ipc: C12Q 1/42 20060101ALI20160622BHEP

INTG Intention to grant announced

Effective date: 20160708

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20161119